Figure 7.

Expansion of nonclassical monocytes in disease-modifying therapy-treated multiple sclerosis (MS) patients. Nonclassical monocytes were identified in blood samples of MS patients, from whom data on disease-modifying therapy [untreated (UT) and disease-modifying therapy (DMT)] were available [UT active progressive MS (PMSa): n = 8, DMT PMSa: n = 6, UT inactive progressive MS (PMSi): n = 8, DMT PMSi: n = 5, UT active relapsing-remitting MS (RRMSa): n = 5, DMT RRMSa: n = 6, UT inactive relapsing-remitting MS (RRMSi): n = 14, and DMT RRMSi: n = 16] as presented in Supplementary Figure S1. Each point denotes a single observation, bars depict group-wise means, and error bars represent SEM. Statistical significance was calculated with two-way analysis of covariance (ANCOVA) (terms: study group, DMT and group: DMT interaction) with age and sex as confounders. Results of the two-way ANCOVA are presented under the plots. post hoc testing was performed with Benjamini–Hochberg-corrected two-tailed T tests. Significant results of post hoc test are presented within the plots. (A) Levels of nonclassical monocytes expressed as percentage of CD45⁺ blood leukocytes. (B) Levels of nonclassical monocytes expressed as counts per microliter of whole blood.